116 related articles for article (PubMed ID: 10741546)
21. Subtype-selective antagonism of NMDA receptors by nylidrin.
Whittemore ER; Ilyin VI; Konkoy CS; Woodward RM
Eur J Pharmacol; 1997 Oct; 337(2-3):197-208. PubMed ID: 9430414
[TBL] [Abstract][Full Text] [Related]
22. Subtype selective NMDA receptor antagonists: evaluation of some novel alkynyl analogues.
Kornberg BE; Nikam SS; Wright JL; Kesten SR; Meltzer LT; Coughenour L; Barr B; Serpa KA; McCormick J
Bioorg Med Chem Lett; 2004 Mar; 14(5):1213-6. PubMed ID: 14980668
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers.
Hu LY; Guo J; Magar SS; Fischer JB; Burke-Howie KJ; Durant GJ
J Med Chem; 1997 Dec; 40(26):4281-9. PubMed ID: 9435897
[TBL] [Abstract][Full Text] [Related]
24. Indole-2-carboxamides as novel NR2B selective NMDA receptor antagonists.
Borza I; Kolok S; Gere A; Agai-Csongor E; Agai B; Tárkányi G; Horváth C; Barta-Szalai G; Bozó E; Kiss C; Bielik A; Nagy J; Farkas S; Domány G
Bioorg Med Chem Lett; 2003 Nov; 13(21):3859-61. PubMed ID: 14552795
[TBL] [Abstract][Full Text] [Related]
25. Antagonists selective for NMDA receptors containing the NR2B subunit.
Chenard BL; Menniti FS
Curr Pharm Des; 1999 May; 5(5):381-404. PubMed ID: 10213801
[TBL] [Abstract][Full Text] [Related]
26. Subtype-selective antagonism of N-methyl-D-aspartate receptor ion channels by synthetic conantokin peptides.
Sheng Z; Dai Q; Prorok M; Castellino FJ
Neuropharmacology; 2007 Jul; 53(1):145-56. PubMed ID: 17588620
[TBL] [Abstract][Full Text] [Related]
27. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and pharmacological evaluation of conformationally constrained glutamic acid higher homologues.
Tamborini L; Cullia G; Nielsen B; De Micheli C; Conti P; Pinto A
Bioorg Med Chem; 2016 Nov; 24(22):5741-5747. PubMed ID: 27658797
[TBL] [Abstract][Full Text] [Related]
29. 2-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists.
Büttelmann B; Alanine A; Bourson A; Gill R; Heitz MP; Mutel V; Pinard E; Trube G; Wyler R
Bioorg Med Chem Lett; 2003 Mar; 13(5):829-32. PubMed ID: 12617901
[TBL] [Abstract][Full Text] [Related]
30. In vitro characterization of novel NR2B selective NMDA receptor antagonists.
Kiss L; Cheng G; Bednar B; Bednar RA; Bennett PB; Kane SA; McIntyre CJ; McCauley JA; Koblan KS
Neurochem Int; 2005 May; 46(6):453-64. PubMed ID: 15769547
[TBL] [Abstract][Full Text] [Related]
31. Synthesis of 2-substituted-6,8-dichloro-3,4-dihydro-3-oxo-2H-1,4-benzothiazine-1,1-d ioxides and -1-oxides as glycine-NMDA receptor antagonists.
Varano F; Catarzi D; Colotta V; Filacchioni G; Cecchi L; Galli A; Costagli C
Farmaco; 1998 Dec; 53(12):752-7. PubMed ID: 10230056
[TBL] [Abstract][Full Text] [Related]
32. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
Nash JE; Brotchie JM
Mov Disord; 2002 May; 17(3):455-66. PubMed ID: 12112191
[TBL] [Abstract][Full Text] [Related]
33. CP-101606 Pfizer Inc.
Chazot PL
Curr Opin Investig Drugs; 2000 Nov; 1(3):370-4. PubMed ID: 11249721
[TBL] [Abstract][Full Text] [Related]
34. Structure-activity relationship for a series of 2-substituted 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles: potent subtype-selective inhibitors of N-methyl-D-aspartate (NMDA) receptors.
Tamiz AP; Whittemore ER; Woodward RM; Upasani RB; Keana JF
Bioorg Med Chem Lett; 1999 Jun; 9(11):1619-24. PubMed ID: 10386947
[TBL] [Abstract][Full Text] [Related]
35. The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on NMDA receptor-mediated EPSCs.
Barton ME; White HS; Wilcox KS
Epilepsy Res; 2004 Mar; 59(1):13-24. PubMed ID: 15135163
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist.
Gill R; Alanine A; Bourson A; Buttelmann B; Fischer G; Heitz MP; Kew JN; Levet-Trafit B; Lorez HP; Malherbe P; Miss MT; Mutel V; Pinard E; Roever S; Schmitt M; Trube G; Wybrecht R; Wyler R; Kemp JA
J Pharmacol Exp Ther; 2002 Sep; 302(3):940-8. PubMed ID: 12183650
[TBL] [Abstract][Full Text] [Related]
37. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and structure-activity relationships of 1,2,3,4-tetrahydroquinoline-2,3,4-trione 3-oximes: novel and highly potent antagonists for NMDA receptor glycine site.
Cai SX; Zhou ZL; Huang JC; Whittemore ER; Egbuwoku ZO; Lü Y; Hawkinson JE; Woodward RM; Weber E; Keana JF
J Med Chem; 1996 Aug; 39(17):3248-55. PubMed ID: 8765507
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and structure-activity relationships of substituted 1,4-dihydroquinoxaline-2,3-diones: antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors.
Keana JF; Kher SM; Cai SX; Dinsmore CM; Glenn AG; Guastella J; Huang JC; Ilyin V; Lü Y; Mouser PL
J Med Chem; 1995 Oct; 38(22):4367-79. PubMed ID: 7473565
[TBL] [Abstract][Full Text] [Related]
40. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.
Wessell RH; Ahmed SM; Menniti FS; Dunbar GL; Chase TN; Oh JD
Neuropharmacology; 2004 Aug; 47(2):184-94. PubMed ID: 15223297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
